

Innate immunity, inflammation and tumour progression: double-edged swords

■ A. Mantovani^{1,2,3} , A. Ponzetta¹ , A. Inforzato^{1,2}  & S. Jaillon^{1,2} 

From the ¹Humanitas Clinical and Research Center - IRCCS, via Manzoni 56, 20089, Rozzano, (Mi), ; ²Department of Biomedical Sciences, Humanitas University, Pieve Emanuele Milan, Italy; and ³The William Harvey Research Institute, Queen Mary University of London, London, EC1M 6BQ, UK

Content List – 15th Key symposium – “Innate immunity”.

Abstract. Mantovani A, Ponzetta A, Inforzato A, Jaillon S (Humanitas Clinical and Research Center - IRCCS, Rozzano (Mi); Humanitas University; Pieve Emanuele (Mi), Italy; The William Harvey Research Institute, Queen Mary University of London, London, UK). Innate immunity, inflammation and tumour progression: double-edged swords. *J Intern Med* 2019; **285**: 524–532.

Components of the cellular and the humoral arm of the immune system are essential elements of the tumour microenvironment (TME). The TME includes tumour-associated macrophages which

have served as a paradigm for the cancer-promoting inflammation. Cytokines, IL-1 in particular, and complement have emerged as important players in tumour promotion. On the other hand, myeloid cells, innate lymphoid cells and complement have the potential, if unleashed, to mediate anticancer resistance. Targeting checkpoints restraining innate immunity, macrophages and natural killer (NK) cells in particular holds promise as a therapeutic strategy.

Keywords: inflammation, innate immunity, interleukin-1, macrophages, tumour microenvironment.

Introduction

The tumour microenvironment (TME) represents an ecological niche in which carcinogenesis and cancer progression occur [1–5]. At the turn of the millennium, a cancer cell-centric view dominated oncology [6]. The TME is now recognized as an important component of cancer [1–5, 7].

Immunity-related components of the TME include tumour-promoting inflammation, reflecting innate immunity and taming of effective adaptive immunity. In general, inflammatory cells in the TME contribute to an immunosuppressive microenvironment.

Components of cancer-related inflammation include myeloid cells (macrophages and neutrophils), basophils and eosinophils [2]. Moreover, elements of the humoral arm of innate immunity are also present *in situ* and play a role in the TME [8, 9]. These include fluid phase pattern recognition molecules and regulators of the complement cascade such as PTX3 [8] and complement components [9].

Macrophages have served as a paradigm for the diversity, complexity and protumour role of inflammation in the TME [4]. Tumour-associated macrophages (TAM) are present in all tumours, contribute to progression and inhibit effective innate and adaptive responses.

Here, major selected aspects of innate immunity and inflammation in cancer will be summarized. Recent results on therapeutic targeting will be emphasized. Moreover, the emerging relevance of innate lymphoid cell and myeloid cell checkpoints will be discussed.

Local and systemic inflammation in tumour promotion

Inflammation and cancer are closely linked. The identification of this connection was in a way an intuition that can be traced to Virchow in the 19th century [5]. The links at a tissue level and at a systemic organism level connecting inflammation and cancer are schematically depicted in Fig. 1. Selected chronic nonresolving inflammatory conditions are a risk factor for developing tumours [2]. For instance, inflammatory bowel




Fig. 1 Links between inflammation and cancer at tissue and organism level.

disease predisposes to colorectal carcinoma and chronic obstructive pulmonary disease to lung cancer.

In the so-called intrinsic pathway, dominant and recessive oncogenes orchestrate an inflammatory microenvironment in cancers with no epidemiological connection to inflammatory conditions (e.g. gliomas). Indeed, cancer-driving genetic events determine the build-up of an inflammatory microenvironment [2]. Tumours unrelated in their natural history to clinical inflammatory conditions are characterized by a TME with inflammatory cells and mediators. For instance, in the TME of breast cancer macrophages are present and enhance growth and metastasis [10]. In particular, in triple negative breast cancer tumour-associated macrophages (TAM) are abundant and their levels are associated with poor prognosis [11]. The tyrosine kinase MER causes epithelial-to-mesenchymal transition and is also an important driver of TAM accumulation in breast cancer [12].

At a systemic level, obesity causes a subclinical inflammation state and is associated to an increased risk to develop cancer, in this same extrinsic pathway perspective (Fig. 1). In addition, inflammation is a crucial component of senescence at a cellular and organism (inflammaging) level and cancer is a disease of ageing [13]. Irrespective of the

pathways involved, smouldering, nonresolving inflammation acts as a propeller of malignant progression [14].

Therefore, the TME is now considered an essential element of cancer and the field moved from a prevailing cancer cell-centric view of the essence of cancer [2, 6, 15] to one that encompasses the TME. The intrinsic and extrinsic pathways intersect at the level of transcription factors (e.g. NFκB; STAT3), cytokines (e.g. IL-1; TNF) and chemokines. Thus, inflammatory cells and mediators are components of the TME and are now considered an essential property of cancer [2, 7].

The TME has specific features in cancers in different organs contexts and in tumours of different types in the same organ or tissue. With the same gross histologic type, tumours can be distinguished based on widely different TME. For instance, in colorectal cancer four TME phenotypes have been identified based on profiling [1].

Mononuclear phagocytes have provided a paradigm of cancer-related inflammation. Other inflammatory cells in the TME are neutrophils, eosinophils and basophils [16]. Inflammatory cells, TAM in particular, promote tissue invasion, intravasation and metastasis, serving as a component of the niche for tumour cells disseminating at distant sites [17, 18]. Immunocompetent cells in tumours produce

cytokines and chemokines that stimulate epithelial-to-mesenchymal (EMT) transition, which can be the first step of tumour invasion. Besides promoting EMT, TAM secrete mediators which stimulate cell migration and dissemination, such as proteolytic enzymes (serine proteases and cathepsins), cytokines (IL-1) and growth factors (epidermal growth factor; EGF) [4, 19–22].

Neutrophils also contribute to the metastatic process, enhancing extravasation, tissue invasion, survival and growth of tumour cell at secondary sites [18, 23]. Other cells in the TME favour dissemination, including immature myeloid cells or T regulatory (Treg) cells. These cells are potent inhibitors of adaptive immune responses to growing tumours. Cancer-associated fibroblasts serve more than a scaffold for the tumour tissue because they regulate immunity and interact with cancer cells. Finally, platelets affect thrombosis, inflammation and tumour cell survival [24, 25]. In summary, the TME contains a variety of immunocompetent cells which enhance dissemination and metastasis.

Cells of the monocyte–macrophage lineage are a major driver of immunosuppression in the microenvironment [4]. Mononuclear phagocytes are endowed with a complex armamentarium of immunosuppressive mediators such as cytokines (IL-10 and TGF β), amino acid metabolites, prostaglandins, NO and triggers of checkpoint blockade such as PD-L1 [4].

Analysis of cellular elements present in the TME can have prognostic value. T-cell infiltration (‘Immunoscore’) is an independent positive parameter associated with more favourable prognosis in colorectal cancer and other tumours [26]. In contrast, TAM infiltration usually has bad prognostic significance [27]. Colorectal cancer is an exception because evidence suggests that TAM infiltration predicts response to 5-fluorouracil containing therapeutic regimens [28].

Tumour-associated macrophages are considered targets for therapy [4]. Targeting TAM plays an important role in the therapeutic activity of trabectedin, a chemotherapeutic drug approved by the European Medicines Agency (EMA) and by the Food and Drug Administration (FDA) [29, 30]. This finding provided proof of principle for the potential value of TAM-directed strategies. Following work in mouse models, antibodies or simple molecules targeting the colony-stimulating factor-1 (CSF1)

pathway have entered clinical assessment together with checkpoint blockade inhibitors [31]. Macrophages can also mediate antitumour activity, when ‘re-educated’, in the presence of antitumour antibodies, or when checkpoints are removed [4] (Fig. 2). As true in general for inflammation and innate immunity, macrophages can act as a double-edged sword (Fig. 2). Emerging innate immunity checkpoints will be discussed below in Section ‘Novel checkpoints in innate immunity’.

Humoral innate immunity, complement, ptx3 and cancer

Molecules belonging to the humoral arm of innate immunity are components of the TME and have recently been shown to contribute to tumour progression [8]. Complement can kill cancer cells. However, preclinical and clinical results now indicate that complement can contribute to tumour-promoting inflammation [9]. Consistently with the concept of complement as an enhancer of tumour promotion, the humoral pattern recognition molecule PTX3 has been identified to act as an extrinsic oncosuppressor gene [8]. In 3-Methylcholanthrene (3-MCA)- and 7,12-dimethylbenz[α]anthracene/terephthalic acid (DMBA/TPA)-induced skin carcinogenesis, myeloid cells and endothelial cells produce PTX3. In PTX3-deficient hosts, tumours displayed increased macrophage infiltration, cytokine production, angiogenesis, complement C3 deposition and C5a levels. This picture indicated enhanced cancer-related inflammation and complement activation. C3-genetic inactivation and CCL2-inhibition inhibited the enhanced susceptibility to 3-MCA carcinogenesis and the M2-like characteristics and recruitment of TAM in PTX3-deficient hosts. PTX3 acted as a regulator of C3-deposition on cancer cells by interacting with the complement inhibitor factor H [8]. Interestingly, PTX3 deficiency resulted in increased DNA damage, as shown by more mutations of *Trp53*, one of the genes targeted by 3-MCA, oxidative DNA damage and expression of DNA damage markers [8]. Importantly, in selected human mesenchymal and epithelial tumours, the *PTX3* promoter and regulatory regions were highly methylated and this epigenetic modification resulted in transcriptional inactivation and silencing of PTX3 expression. In colorectal cancer, PTX3 gene methylation and silencing was detected as an early event, already identified in adenomas and stage 1 neoplastic lesions, an observation consistent with an important role in pathogenesis [8].

As a biomarker in the clinic, PTX3 was found to act as a local or systemic indicator of cancer-related




Fig. 2 The macrophage balance. Macrophages can exert a dual function in the tumour microenvironment. In established clinical tumours, the protumour function of TAM prevail. Macrophages serve as a paradigm for tumour-promoting inflammation

inflammation. In particular, PTX3 was present at high levels in soft tissue sarcomas [32], lung cancer [33, 34], myeloproliferative neoplasms [35], pancreatic carcinoma [36], gliomas [37] and hepatocellular carcinoma [38], in some settings correlating with cancer progression. In the case of lung cancer, different studies reported increased systemic and local PTX3 levels and a correlation with disease aggressiveness and progression [33, 34]. Interestingly, in contrast with other epithelial cells that are poor producers of PTX3, lung epithelial cells express PTX3 in inflammatory conditions via JNK [39]. These results indicate that cancer-related inflammation may impact on PTX3 production in lung cancer cells. Along the same line, in myeloproliferative neoplasms, PTX3 levels correlated with mutant JAK2 (JAK2V617F) allele burden [35, 40], which is well established to sustain leucocyte activation.

In conclusion, in preclinical models and in some human tumours (e.g. colorectal cancer) PTX3 functions as an extrinsic oncosuppressor gene, taming complement-driven macrophage-mediated tumour promotion. In other cancers, elevated PTX3 levels reflect systemic inflammation or genetic events that drive carcinogenesis as is the case for JAK2 in myeloproliferative neoplasms.

IL-1 in tumour promotion and its clinical translation

IL-1 is a major mediator connecting inflammation and tumour promotion. IL-1 α and IL-1 β in cancer are a major mechanism of tumour promotion although early in carcinogenesis, IL-1 α may trigger an antitumour role as an antitumour response [41]. It was originally shown that IL-1 β increased metastasis in mouse models [42–45]. IL-1 α and IL-1 β were found to be induced by RAS and RET-PTC oncogenes [46, 47]. IL-1 β was also found in the process of carcinogenesis driven by chronic inflammation in the gastrointestinal tract [48]. In skin carcinogenesis, IL-1 α was downstream of RAS, affecting transformed cells and the TME [46].

In different murine and human tumour types, including sarcomas, melanoma, pancreatic carcinoma [49–52], myelomas [53] and breast carcinomas [54], a major mechanism of IL-1-mediated promotion has been shown to be the expansion and immunosuppressive function of myeloid cells [55, 56]. In mouse and human melanoma, IL-1 caused upregulation of TET2 in myeloid cells. TET2 is a DNA methylcytosine dioxygenase which induced immunosuppression in M2-like TAM [56]. Endothelial cells are regulated by IL-1 by promoting angiogenesis. IL-1 induced endothelial cell adhesion molecules E-selectin and vascular cell

adhesion molecule-1 (VCAM-1) resulting in augmentation of metastasis.

An IL-1 β signature was identified in the peripheral blood mononuclear cells from 145 patients with metastatic, hormone-negative breast cancer [54]. When treated with daily IL-1 receptor antagonist (IL-1Ra, anakinra) for 2 weeks, the IL-1 β signature decreased [54]. Thymic stromal cell lymphopoietin (TSLP) is associated with poor prognosis not only in breast cancer but also in other epithelial cancers [57] and correlated with IL-1 β [54, 57]. Human genetics is consistent with a role of IL-1 and related molecules in carcinogenesis [58–63]. Therefore, mouse evidence and human genetics suggest that IL-1 is a driver of tumour promotion.

These results provided a rational for therapeutic translation of IL-1 blocking strategies using anakinra or anti-IL-1 α or IL-1 β mAb. Anakinra with dexamethasone in 47 patients with smouldering myeloma resulted in significantly increase in survival [53, 64]. Anakinra was also added to the standard of therapy with fluorouracil in advanced metastatic colorectal cancer [65], hormone-negative breast cancer [54] and in advanced pancreatic cancer [66, 67]. IL-1 α had long been known to mediate muscle loss and cachexia [48]. Three trials have administered anti-IL-1 α to patients with advanced cancers of various origins [68, 69] as well as patients with colorectal cancer [70]. Blocking IL-1 resulted in an increase in lean body mass, improved parameters of quality of life, decreased pain and decreased constitutional symptoms. [71]. Reducing IL-1 α may also reduce inflammation-mediated immunosuppression, both impacting on increased survival and immune-mediated tumour regression [2].

Preclinical and clinical data since 1990 provided a background for assessing the impact of blocking IL-1 β in human cancer development. In the seminal CANTOS study with 10,061 patients with atherosclerosis and high CRP levels, anti-IL-1 β (Canakinumab) resulted in a major (>50%) reduction in the incidence and mortality from lung cancer [72]. Blocking IL-1-driven recruitment and immunosuppressive function of macrophages is likely to play a major role in these impressive results.

Novel checkpoints in innate immunity

Adaptive T cell-orchestrated immunity and its subversion are central in the control of

carcinogenesis and progression. Recent results have shed new light on the long-overlooked role of innate lymphoid cells (ILC) [73–75]. NK cells are a population of ILCs which has not been credited to play a major role in resistance against solid tumour carcinogenesis. NK cells are a component of resistance against leukaemia and lymphomas and restrain haematogenous metastasis. The differentiation and activity of NK cells is also controlled by negative regulators. The member of the IL-1 receptor family IL-1R8 has recently been shown to serve as a checkpoint for IL-18-induced differentiation and activation of NK cells and ILC1 cells [76]. In an independent study, it was found that IL-37, produced by Treg cells, suppressed NK function via IL-1R8 [77]. Inhibition of IL-1R8 unleashed NK cell-mediated resistance against liver and lung carcinogenesis and metastasis, two NK cell-rich anatomical sites [76]. The checkpoint activity of IL-1R8 was also detected in human NK cells. These results suggest that IL-1R8 can serve as a double-edged sword in carcinogenesis. On the one hand, it inhibits tumour-promoting inflammation; on the other hand, it acts as a checkpoint for NK cells which, if unleashed, can mediate anticancer immunity at distant organs rich in NK cells. In agreement with these results, in breast cancer IL-1R8 expression was found to be associated with an NK cell-inflamed molecular signature [78]. These results suggest that targeting the IL-1R8 checkpoint may of value in particular in the context of liver metastasis. IL-1R8 adds to the diverse number of negative regulators which keep NK cells under control [74, 79].

As discussed for NK cells and generally true for immunocompetent cells, the function of myelomonocytic cells is held in check by molecular brakes (checkpoints). CD47 is a ‘don’t eat me’ signal recognized by SIRP α on macrophages. It regulates the phagocytosis of effete normal cells, erythrocytes in particular [80]. Interestingly, the c-myc oncogene induces expression of CD47 and PD-L1 [81]. Preclinical evidence showed that blocking the CD47-SIRP α checkpoint unleashed antibody-dependent cellular phagocytosis (ADCP). The antitumour activity of ADCP can synergize with anti-CD20 in lymphoma killing [82]. Indeed, it has been known since the late 1970’s that macrophages are potent effectors of antibody-dependent tumour cell killing [4] and preclinical and clinical evidence is consistent with the *in vivo* relevance of this function [4, 83]. Interestingly, signals which orient TAM in a protumour direction (M2-like) do

not inhibit their ADCC and ADCP effector function, or actually increase it [83]. Thus, seemingly paradoxically, in the presence of antitumour mAb TAM may well be suited to mediate ADCC-ADCP after checkpoint blockade.

In a Phase 1b [84], a monoclonal antibody (mAb, 5F9) blocking the CD47 checkpoint of macrophage function in concert with anti-CD20 (rituximab) had significant antitumour activity in refractory diffuse large B-cell lymphoma and follicular lymphoma. These results [84] are noteworthy not only because of their own clinical merit (mild side effects; frequency, rapidity and durability of responses) but also because they have more in general implications for cancer immunotherapy [85].

Concluding remarks

Immunity and inflammation are essential elements of the tumour TME which provides a nurturing niche for cancer [1, 5, 7]. Inflammatory cells, TAM in particular, promote invasion dissemination and metastasis. Progression of cancer to invasion and metastasis and evasion from immunity are associated with immunosuppressive pathways on innate and adaptive antitumour immune responses. Immunosuppression is mediated by suppressive cells of the myeloid lineage, triggering of checkpoint blockade, induction and recruitment of Treg cells.

Quantitative analysis of the immune and inflammatory components of the TME has resulted in the identification of novel prognostic factors associated with clinical cancer progression as illustrated by the immunoscore for T cells and by TAM analysis. Genomic approaches have added vistas to the analysis of the TME and to candidate new classifications of cancers. Finally, better understanding of the mechanism of action of conventional chemotherapeutic strategies, the therapeutic outcome of checkpoint blockade inhibitors, the introduction of therapeutic antibodies and, very recently, therapies based on adoptive transfer of immunocompetent cells for leukaemias and lymphomas [86–88] have unequivocally shown that the immune responses can be manipulated to cure metastatic tumours.

The emergence of novel checkpoints acting on myeloid and innate lymphoid cells [76, 84, 85] may provide tools for innovative approaches. In the same vein, the impressive results discussed

above blocking IL-1 in patients [89] offer promise for new approaches blocking tumour-promoting inflammation.

Acknowledgements

Alberto Mantovani is supported by European Commission (ERC project PHII-669415), Ministero dell'Istruzione, dell'Università e della Ricerca (MIUR) (project PRIN 2015YYKPN), Associazione Italiana per la Ricerca sul Cancro (AIRC IG 19014; AIRC 5x1000 9962 and 21147), and Italian Ministry of Health. Sebastien Jaillon is supported by a grant from the Associazione Italiana per la Ricerca sul Cancro (AIRC-CID18475); Antonio Inforzato is supported by Italian Ministry of Health (GR-2011-02349539) and Fondazione Beppe e Nuccy Angiolini; Andrea Ponzetta is recipient of a fellowship from the Fondazione Umberto Veronesi (FUV).

Conflict of interest statement

AM is inventor of IP, received consultancy honoraria and royalties related to molecules involved in inflammation.

References

- 1 Fridman WH, Zitvogel L, Sautes-Fridman C, Kroemer G. The immune contexture in cancer prognosis and treatment. *Nat Rev Clin Oncol* 2017; **14**: 717–34.
- 2 Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. *Nature* 2008; **454**: 436–44.
- 3 Mantovani A, Romero P, Palucka AK, Marincola FM. Tumour immunity: effector response to tumour and role of the microenvironment. *Lancet* 2008; **371**: 771–83.
- 4 Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P. Tumour-associated macrophages as treatment targets in oncology. *Nat Rev Clin Oncol* 2017; **14**: 399–416.
- 5 Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? *Lancet* 2001; **357**: 539–45.
- 6 Hanahan D, Weinberg RA. The hallmarks of cancer. *Cell* 2000; **100**: 57–70.
- 7 Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell* 2011; **144**: 646–74.
- 8 Bonavita E, Gentile S, Rubino M *et al.* PTX3 is an extrinsic oncosuppressor regulating complement-dependent inflammation in cancer. *Cell* 2015; **160**: 700–14.
- 9 Reis ES, Mastellos DC, Ricklin D, Mantovani A, Lambris JD. Complement in cancer: untangling an intricate relationship. *Nat Rev Immunol* 2018; **18**: 5–18.
- 10 Medrek C, Ponten F, Jirstrom K, Leandersson K. The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients. *BMC Cancer* 2012; **12**: 306.

- 11 Zhang WJ, Wang XH, Gao ST *et al.* Tumor-associated macrophages correlate with phenomenon of epithelial-mesenchymal transition and contribute to poor prognosis in triple-negative breast cancer patients. *J Surg Res* 2018; **222**: 93–101.
- 12 Schoumacher M, Burbridge M. Key roles of AXL and MER receptor tyrosine kinases in resistance to multiple anticancer therapies. *Curr Oncol Rep* 2017; **19**: 19.
- 13 Bottazzi B, Riboli E, Mantovani A. Aging, inflammation and cancer. *Semin Immunol* 2018; **40**: 74–82.
- 14 Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. *Cancer Cell* 2005; **7**: 211–7.
- 15 Mantovani A. Cancer: inflaming metastasis. *Nature* 2009; **457**: 36–7.
- 16 Galdiero MR, Varricchi G, Loffredo S, Mantovani A, Marone G. Roles of neutrophils in cancer growth and progression. *J Leukoc Biol* 2018; **103**: 457–64.
- 17 Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. *Immunity* 2014; **41**: 49–61.
- 18 de Mingo Pulido A, Ruffell B. Immune regulation of the metastatic process: implications for therapy. *Adv Cancer Res* 2016; **132**: 139–63.
- 19 Qian BZ, Li J, Zhang H *et al.* CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. *Nature* 2011; **475**: 222–5.
- 20 Ruffell B, Affara NI, Coussens LM. Differential macrophage programming in the tumor microenvironment. *Trends Immunol* 2012; **33**: 119–26.
- 21 Wyckoff J, Wang W, Lin EY *et al.* A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. *Cancer Res* 2004; **64**: 7022–9.
- 22 Mason SD, Joyce JA. Proteolytic networks in cancer. *Trends Cell Biol* 2011; **21**: 228–37.
- 23 Liang W, Ferrara N. The complex role of neutrophils in tumor angiogenesis and metastasis. *Cancer Immunol Res* 2016; **4**: 83–91.
- 24 Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis. *Nat Rev Cancer* 2011; **11**: 123–34.
- 25 Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. *Nat Rev Cancer* 2009; **9**: 239–52.
- 26 Pages F, Mlecnik B, Marliot F *et al.* International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. *Lancet* 2018; **391**: 2128–39.
- 27 Steidl C, Lee T, Shah SP *et al.* Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. *New England J Med* 2010; **362**: 875–85.
- 28 Malesci A, Bianchi P, Celesti G *et al.* Tumor-associated macrophages and response to 5-fluorouracil adjuvant therapy in stage III colorectal cancer. *Oncoimmunology* 2017; **6**: e1342918.
- 29 Germano G, Frapolli R, Belgiovine C *et al.* Role of macrophage targeting in the antitumor activity of trabectedin. *Cancer Cell* 2013; **23**: 249–62.
- 30 D'Incalci M, Badri N, Galmarini CM, Allavena P. Trabectedin, a drug acting on both cancer cells and the tumour microenvironment. *Br J Cancer* 2014; **111**: 646–50.
- 31 Ries CH, Cannarile MA, Hoves S *et al.* Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. *Cancer Cell* 2014; **25**: 846–59.
- 32 Germano G, Frapolli R, Simone M *et al.* Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. *Can Res* 2010; **70**: 2235–44.
- 33 Planque C, Kulasingam V, Smith CR, Reckamp K, Goodglick L, Diamandis EP. Identification of five candidate lung cancer biomarkers by proteomics analysis of conditioned media of four lung cancer cell lines. *Mol Cell Proteom* 2009; **8**: 2746–58.
- 34 Infante M, Allavena P, Garlanda C *et al.* Prognostic and diagnostic potential of local and circulating levels of pentraxin 3 in lung cancer patients. *Int J Cancer* 2016; **138**: 983–91.
- 35 Barbui T, Carobbio A, Finazzi G *et al.* Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3. *Haematologica* 2011; **96**: 315–8.
- 36 Kondo S, Ueno H, Hosoi H *et al.* Clinical impact of pentraxin family expression on prognosis of pancreatic carcinoma. *Br J Cancer* 2013; **109**: 739–46.
- 37 Locatelli M, Ferrero S, Martinelli Boneschi F *et al.* The long pentraxin PTX3 as a correlate of cancer-related inflammation and prognosis of malignancy in gliomas. *J Neuroimmunol* 2013; **260**: 99–106.
- 38 Carmo RF, Aroucha D, Vasconcelos LR, Pereira LM, Moura P, Cavalcanti MS. Genetic variation in PTX3 and plasma levels associated with hepatocellular carcinoma in patients with HCV. *J Viral Hepat* 2016; **23**: 116–22.
- 39 Han B, Mura M, Andrade CF *et al.* TNFalpha-induced long pentraxin PTX3 expression in human lung epithelial cells via JNK. *J Immunol* 2005; **175**: 8303–11.
- 40 Lussana F, Carobbio A, Salmoiraghi S *et al.* Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera. *J Hematol Oncol* 2017; **10**: 54.
- 41 Song X, Voronov E, Dvorkin T *et al.* Differential effects of IL-1 alpha and IL-1 beta on tumorigenicity patterns and invasiveness. *J Immunol* 2003; **171**: 6448–56.
- 42 Giavazzi R, Garofalo A, Bani MR *et al.* Interleukin 1-induced augmentation of experimental metastases from a human melanoma in nude mice. *Cancer Res* 1990; **50**: 4771–5.
- 43 Chirivi RG, Garofalo A, Padura IM, Mantovani A, Giavazzi R. Interleukin 1 receptor antagonist inhibits the augmentation of metastasis induced by interleukin 1 or lipopolysaccharide in a human melanoma/nude mouse system. *Cancer Res* 1993; **53**: 5051–4.
- 44 Vidal-Vanaclocha F, Amezaga C, Asumendi A, Kaplanski G, Dinarello CA. Interleukin-1 receptor blockade reduces the number and size of murine B16 melanoma hepatic metastases. *Cancer Res* 1994; **54**: 2667–72.
- 45 Voronov E, Shouval DS, Krelin Y *et al.* IL-1 is required for tumor invasiveness and angiogenesis. *Proc Natl Acad Sci USA* 2003; **100**: 2645–50.
- 46 Cataisson C, Salcedo R, Hakim S *et al.* IL-1R-MyD88 signaling in keratinocyte transformation and carcinogenesis. *J Exp Med* 2012; **209**: 1689–702.
- 47 Borrello MG, Alberti L, Fischer A *et al.* Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene. *Proc Natl Acad Sci USA* 2005; **102**: 14825–30.
- 48 Garlanda C, Dinarello CA, Mantovani A. The interleukin-1 family: back to the future. *Immunity* 2013; **39**: 1003–18.
- 49 Ling J, Kang Y, Zhao R *et al.* KrasG12D-induced IKK2/beta/NF-kappaB activation by IL-1alpha and p62 feedforward

- loops is required for development of pancreatic ductal adenocarcinoma. *Cancer Cell* 2012; **21**: 105–20.
- 50 Melisi D, Niu J, Chang Z *et al.* Secreted interleukin-1alpha induces a metastatic phenotype in pancreatic cancer by sustaining a constitutive activation of nuclear factor-kappaB. *Mol Cancer Res* 2009; **7**: 624–33.
- 51 Zhuang Z, Ju HQ, Aguilar M *et al.* IL1 receptor antagonist inhibits pancreatic cancer growth by abrogating NF-kappaB activation. *Clin Cancer Res* 2016; **22**: 1432–44.
- 52 Tjomsland V, Bojmar L, Sandstrom P *et al.* IL-1alpha expression in pancreatic ductal adenocarcinoma affects the tumor cell migration and is regulated by the p38MAPK signaling pathway. *PLoS ONE* 2013; **8**: e70874.
- 53 Lust JA, Lacy MQ, Zeldenrust SR *et al.* Reduction in C-reactive protein indicates successful targeting of the IL-1/IL-6 axis resulting in improved survival in early stage multiple myeloma. *Am J Hematol* 2016; **91**: 571–4.
- 54 Wu TC, Xu K, Martinek J *et al.* IL1 receptor antagonist controls transcriptional signature of inflammation in patients with metastatic breast cancer. *Cancer Res* 2018; **78**: 5243–58.
- 55 Elkabets M, Ribeiro VS, Dinarello CA *et al.* IL-1beta regulates a novel myeloid-derived suppressor cell subset that impairs NK cell development and function. *Eur J Immunol* 2010; **40**: 3347–57.
- 56 Pan W, Zhu S, Qu K *et al.* The DNA methylcytosine dioxygenase Tet2 sustains immunosuppressive function of tumor-infiltrating myeloid cells to promote melanoma progression. *Immunity* 2017; **47**: e5.
- 57 Kuan EL, Ziegler SF. A tumor-myeloid cell axis, mediated via the cytokines IL-1alpha and TSLP, promotes the progression of breast cancer. *Nat Immunol* 2018; **19**: 366–74.
- 58 El-Omar EM, Carrington M, Chow WH *et al.* Interleukin-1 polymorphisms associated with increased risk of gastric cancer. *Nature* 2000; **404**: 398–402.
- 59 Lind H, Zienolddiny S, Ryberg D, Skaug V, Phillips DH, Haugen A. Interleukin 1 receptor antagonist gene polymorphism and risk of lung cancer: a possible interaction with polymorphisms in the interleukin 1 beta gene. *Lung Cancer* 2005; **50**: 285–90.
- 60 Bhat IA, Naykoo NA, Qasim I *et al.* Association of interleukin 1 beta (IL-1beta) polymorphism with mRNA expression and risk of non small cell lung cancer. *Meta Gene* 2014; **2**: 123–33.
- 61 Zienolddiny S, Ryberg D, Maggini V, Skaug V, Canzian F, Haugen A. Polymorphisms of the interleukin-1 beta gene are associated with increased risk of non-small cell lung cancer. *Int J Cancer* 2004; **109**: 353–6.
- 62 Hu Z, Shao M, Chen Y *et al.* Allele 2 of the interleukin-1 receptor antagonist gene (IL1RN*2) is associated with a decreased risk of primary lung cancer. *Cancer Lett* 2006; **236**: 269–75.
- 63 Khazim K, Azulay EE, Kristal B, Cohen I. Interleukin 1 gene polymorphism and susceptibility to disease. *Immunol Rev* 2018; **281**: 40–56.
- 64 Lust JA, Lacy MQ, Zeldenrust SR *et al.* Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1beta-induced interleukin 6 production and the myeloma proliferative component. *Mayo Clin Proc* 2009; **84**: 114–22.
- 65 Isambert N, Hervieu A, Hennequin A *et al.* Fluorouracil plus bevacizumab plus anakinra for patients with metastatic colorectal cancer refractory to standard therapies (IRAFU): an investigator-initiated, open-label, single-arm, multicenter, phase 2 study. *ASCO* 2018; **7**: e1474319 in press.
- 66 Becerra C, Paulson AS, Cavaness K, Hoof PD, Celinski S. Gemcitabine, nab-paclitaxel, cisplatin, and anakinra (AGAP) treatment in patients with non-metastatic pancreatic ductal adenocarcinoma (PDAC). NCT02550327. *J Clin Oncol* 2018; **4**: 449.
- 67 Whiteley A, Becerra C, McCollum D, Paulson AS, Goel A. A pilot, non-randomized evaluation of the safety of anakinra plus FOLFIRINOX in metastatic pancreatic ductal adenocarcinoma patients. *J Clin Oncol* 2016; **34**(suppl): e165750.
- 68 Hong DS, Janku F, Naing A *et al.* Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer. *Invest New Drugs* 2015; **33**: 621–31.
- 69 Hong DS, Hui D, Bruera E *et al.* MABp1, a first-in-class true human antibody targeting interleukin-1alpha in refractory cancers: an open-label, phase 1 dose-escalation and expansion study. *Lancet Oncol* 2014; **15**: 656–66.
- 70 Hickish T, Andre T, Wyrwicz L *et al.* MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study. *Lancet Oncol* 2017; **18**: 192–201.
- 71 McDonald JJ, McMillan DC, Laird BJA. Targeting IL-1alpha in cancer cachexia: a narrative review. *Curr Opin Support Palliat Care* 2018; **12**: 453–9.
- 72 Ridker PM, MacFadyen JG, Everett BM, Libby P, Thuren T, Glynn RJ. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. *Lancet* 2018; **391**: 319–28.
- 73 Molgora M, Supino D, Mavilio D *et al.* The yin-yang of the interaction between myelomonocytic cells and NK cells. *Scand J Immunol* 2018; **88**: e12705.
- 74 Vivier E, Raulet DH, Moretta A *et al.* Innate or adaptive immunity? The example of natural killer cells. *Science* 2011; **331**: 44–9.
- 75 Vivier E, Artis D, Colonna M *et al.* Innate lymphoid cells: 10 years on. *Cell* 2018; **174**: 1054–66.
- 76 Molgora M, Bonavita E, Ponzetta A *et al.* IL-1R8 is a checkpoint in NK cells regulating anti-tumour and anti-viral activity. *Nature* 2017; **551**: 110–4.
- 77 Sarhan D, Hippen KL, Lemire A *et al.* Adaptive NK cells resist regulatory T-cell suppression driven by IL37. *Cancer Immunol Res* 2018; **6**: 766–75.
- 78 Campesato LF, Silva APM, Cordeiro L *et al.* High IL-1R8 expression in breast tumors promotes tumor growth and contributes to impaired antitumor immunity. *Oncotarget* 2017; **8**: 49470–83.
- 79 Bellora F, Castriconi R, Dondero A *et al.* The interaction of human natural killer cells with either unpolarized or polarized macrophages results in different functional outcomes. *Proc Natl Acad Sci USA* 2010; **107**: 21659–64.
- 80 McCracken MN, Cha AC, Weissman IL. Molecular pathways: activating T cells after cancer cell phagocytosis from blockade of CD47 “Don’t Eat Me” signals. *Clin Cancer Res* 2015; **21**: 3597–601.
- 81 Casey SC, Tong L, Li Y *et al.* MYC regulates the antitumor immune response through CD47 and PD-L1. *Science* 2016; **352**: 227–31.

- 82 Chao MP, Alizadeh AA, Tang C *et al.* Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. *Cell* 2010; **142**: 699–713.
- 83 Leidi M, Gotti E, Bologna L *et al.* M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells *in vitro*. *J Immunol* 2009; **182**: 4415–22.
- 84 Advani R, Flinn I, Popplewell L *et al.* CD47 blockade by Hu5F9-G4 and Rituximab in non-Hodgkin's lymphoma. *N Engl J Med* 2018; **379**: 1711–21.
- 85 Mantovani A, Longo DL. Macrophage checkpoint blockade in cancer – back to the future. *New England J Med* 2018; **379**: 1777–9.
- 86 Sadelain M, Riviere I, Riddell S. Therapeutic T cell engineering. *Nature* 2017; **545**: 423–31.
- 87 Anderson KG, Stromnes IM, Greenberg PD. Obstacles posed by the tumor microenvironment to T cell activity: a case for synergistic therapies. *Cancer Cell* 2017; **31**: 311–25.
- 88 Gubin MM, Artyomov MN, Mardis ER, Schreiber RD. Tumor neoantigens: building a framework for personalized cancer immunotherapy. *J Clin Invest* 2015; **125**: 3413–21.
- 89 Ridker PM, MacFadyen JG, Thuren T, Everett BM, Libby P, Glynn RJ. Effect of interleukin-1 beta inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. *Lancet* 2017; **390**: 1833–42.

Correspondence: A. Mantovani, Humanitas Clinical and Research Center, via Manzoni 56, 20089 Rozzano, Milan, Italy. (fax: +39 0282245101; e-mail: alberto.mantovani@humanitasresearch.it). ■